Sheraton Phoenix Downtown
Valley of The Sun Ballroom D, Second Level
340 N 3rd Street
Phoenix, AZ 85004
*Or Virtual, Live Streamed Option
Advanced practice providers and other healthcare professionals involved in the management of patients with multiple sclerosis
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this live material for a maximum of 2.0 AMA PRA Category 1 CreditsTM.
AcademicCME designates this live material for a maximum of 2.0 CNE Contact Hours (2.0 CNE Pharmacotherapeutic Contact Hours).
AcademicCME designates this continuing education activity for 2.0 CPE Contact Hours (0.20 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-25-004-L01-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee associated with this education. There is both an in-person and virtual option of participation.
*Supported by an educational grant from Bristol Myers Squibb
For further conference information or questions, email admin@academiccme.com.
Sheraton Phoenix Downtown
Valley of The Sun Ballroom D, Second Level
340 N 3rd Street
Phoenix, AZ 85004
OR VIRTUAL, LIVE STREAMED OPTION!
Review the updated methods for MS diagnostics including the 2024 McDonald Criteria, biomarkers, and imaging techniques
Evaluate the advances in the mechanisms of action, clinical trial data, and adverse events for disease modifying therapies for patients with multiple sclerosis
Review the mechanism of action and potential role of CAR T-cell therapy in managing neuroinflammation in patients with MS
4:00 pm – 4:45 pm MST: Diagnostic Update – Sarah Morrow, MD, MS and Jiwon Oh, MD
a. McDonald Criteria 2024
i. The Importance of Early Diagnosis and Intervention
ii. Differential Diagnosis and MS Mimics
iii. Biomarkers for Diagnosis and Monitoring Disease Progression
1. CMSC MRI Guidelines
a. Central Vein Sign
b. Paramagnetic Rim Lesion
iv. Emerging Biomarkers
1. NFL and Kappa Light Chains
2. Other Biomarkers
4:45 pm – 5:30 pm MST: Review of Current and Emerging Disease Modifying Therapies and Mitigating Their Adverse Events – Scott D. Newsome, DO and Lisa Marie Fox, PA-C
a. Current Therapies
i. High Efficacy vs. Low to Moderate Efficacy DMTs
ii. Side Effects and Management
iii. Rationale for Treatment Initiation Choice and Treatment Switch
b. Update on BTK Therapeutics
5:30 pm – 6:00 pm MST: The Evolving Role of CAR T Therapeutics in the Management of MS Neuroinflammation – Claire S. Riley, MD
a. Mechanism of Action and Potential Role of CAR T-cell Therapy in Managing Neuroinflammation in Patients with MS
b. Clinical Trial Data for CAR T-cell Therapeutics in Neurology
c. Applications of CAR T-cell Therapy in Oncology and the Transition from Oncology to Neurology
*Supported by an educational grant from Bristol Myers Squibb
4:00 pm – 4:45 pm MST: Diagnostic Update – Sarah Morrow, MD, MS and Jiwon Oh, MD
a. McDonald Criteria 2024
i. The Importance of Early Diagnosis and Intervention
ii. Differential Diagnosis and MS Mimics
iii. Biomarkers for Diagnosis and Monitoring Disease Progression
1. CMSC MRI Guidelines
a. Central Vein Sign
b. Paramagnetic Rim Lesion
iv. Emerging Biomarkers
1. NFL and Kappa Light Chains
2. Other Biomarkers
4:45 pm – 5:30 pm MST: Review of Current and Emerging Disease Modifying Therapies and Mitigating Their Adverse Events – Scott D. Newsome, DO and Lisa Marie Fox, PA-C
a. Current Therapies
i. High Efficacy vs. Low to Moderate Efficacy DMTs
ii. Side Effects and Management
iii. Rationale for Treatment Initiation Choice and Treatment Switch
b. Update on BTK Therapeutics
5:30 pm – 6:00 pm MST: The Evolving Role of CAR T Therapeutics in the Management of MS Neuroinflammation – Claire S. Riley, MD
a. Mechanism of Action and Potential Role of CAR T-cell Therapy in Managing Neuroinflammation in Patients with MS
b. Clinical Trial Data for CAR T-cell Therapeutics in Neurology
c. Applications of CAR T-cell Therapy in Oncology and the Transition from Oncology to Neurology
*Supported by an educational grant from Bristol Myers Squibb
811 S. Orleans Ave. Tampa, Fl 33606
